2022
DOI: 10.1096/fj.202101438rr
|View full text |Cite
|
Sign up to set email alerts
|

Down‐regulated TINAGL1 in fibroblasts impairs wound healing in diabetes

Abstract: Matricellular proteins, a group of extracellular matrix (ECM) proteins, are key regulators of skin repair and their dysregulation impairs wound healing in diabetes. Tubulointerstitial nephritis antigen like 1 (TINAGL1) is a new member of matricellular protein family, and the understanding of its functional role is still relatively limited. In the current study, we detected the expression of TINAGL1 in diabetic skin wound tissues through RT‐PCR, ELISA and Western blot analysis, investigated the contribution of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 30 publications
(59 reference statements)
0
2
0
Order By: Relevance
“…Considering the short half‐life of the recombinant protein, we adopted the method of high dose and multi‐frequency intradermal injection. This refers to several previous studies on the application of recombinant protein in the treatment of diabetic wounds 14–17 . Diabetic mice were injected with 100 μL PDK4 (1 μg) intradermally on Days 0, 3, 5, 7, and 9.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Considering the short half‐life of the recombinant protein, we adopted the method of high dose and multi‐frequency intradermal injection. This refers to several previous studies on the application of recombinant protein in the treatment of diabetic wounds 14–17 . Diabetic mice were injected with 100 μL PDK4 (1 μg) intradermally on Days 0, 3, 5, 7, and 9.…”
Section: Methodsmentioning
confidence: 99%
“…This refers to several previous studies on the application of recombinant protein in the treatment of diabetic wounds. [14][15][16][17] Diabetic mice were injected with 100 μL PDK4 (1 μg) intradermally on Days 0, 3, 5, 7, and 9. At the same time, the diabetic mice in the control group were injected with the same amount of PBS.…”
Section: Animal Experimentsmentioning
confidence: 99%